Vanderbilt-Ingram Cancer Center has been selected as a Blue Distinction Center for Complex and Rare CancersSM by Blue Cross Blue Shield Association, in collaboration with BlueCross BlueShield of Tennessee.

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

Jennifer Pietenpol, Ph.D., Ingram Professor of Cancer Research and professor of Biochemistry, has been named director of Vanderbilt-Ingram Cancer Center.

Women who receive silicone gel-filled breast implants do not have a higher risk of breast cancer or other cancers and do not experience lower survival rates after breast cancer diagnosis, according to a new report published in the November issue of Annals of Plastic Surgery. This is the first exhaustive review in almost a decade of the health effects of cosmetic breast implants.

Men with prostate cancer now may have access to a new, minimally invasive surgical procedure. Urologic surgeons at Vanderbilt-Ingram Cancer Center will be the first in Tennessee to test the new Ablatherm procedure, which uses high-intensity focused ultrasound (HIFU) to destroy cancerous prostate tissue without any incision.

When the dust settles on a new renovation project involving Vanderbilt-Ingram Cancer Center‘s Henry-Joyce Cancer Clinic, waiting room space and exam rooms will nearly double to help meet the needs of an ever increasing number of cancer patients in Middle Tennessee and beyond.

Vanderbilt-Ingram Cancer Center has received a three-year accreditation with commendation, the highest level of approval, from the Commission on Cancer of the American College of Surgeons (ACoS).